Agilent Technologies (NYSE:A) PT Raised to $168.00 at Cowen – MarketBeat
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
Agilent Technologies (NYSE:A – Get Rating) had its price objective increased by equities researchers at Cowen from $160.00 to $168.00 in a note issued to investors on Tuesday, Stock Target Advisor reports. Cowen’s price target would suggest a potential upside of 8.77% from the company’s current price.
Other research analysts also recently issued research reports about the company. Robert W. Baird upped their target price on Agilent Technologies from $160.00 to $170.00 in a report on Tuesday. Cowen increased their price objective on Agilent Technologies from $160.00 to $168.00 in a report on Tuesday. Jefferies Financial Group boosted their target price on shares of Agilent Technologies from $158.00 to $168.00 in a report on Tuesday. Credit Suisse Group initiated coverage on shares of Agilent Technologies in a research report on Wednesday, August 24th. They set an “outperform” rating and a $165.00 price target for the company. Finally, Bank of America upped their price objective on shares of Agilent Technologies from $148.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, August 17th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $157.00.
Agilent Technologies Trading Up 6.4 %
NYSE:A traded up $9.32 during mid-day trading on Tuesday, reaching $154.46. 48,340 shares of the company’s stock traded hands, compared to its average volume of 1,249,900. The company has a 50 day moving average price of $133.08 and a 200-day moving average price of $128.04. The firm has a market capitalization of $45.73 billion, a price-to-earnings ratio of 35.18, a PEG ratio of 2.67 and a beta of 1.06. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.94 and a quick ratio of 1.41. Agilent Technologies has a 12-month low of $112.52 and a 12-month high of $165.68.
Agilent Technologies (NYSE:A – Get Rating) last announced its earnings results on Monday, November 21st. The medical research company reported $1.53 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.14. The company had revenue of $1.85 billion during the quarter, compared to the consensus estimate of $1.76 billion. Agilent Technologies had a return on equity of 28.46% and a net margin of 19.94%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.21 earnings per share. On average, sell-side analysts predict that Agilent Technologies will post 5.07 earnings per share for the current year.
Insider Transactions at Agilent Technologies
In other news, CEO Michael R. Mcmullen sold 6,775 shares of the stock in a transaction on Wednesday, October 19th. The stock was sold at an average price of $130.11, for a total transaction of $881,495.25. Following the transaction, the chief executive officer now directly owns 191,358 shares of the company’s stock, valued at approximately $24,897,589.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Agilent Technologies news, CEO Michael R. Mcmullen sold 6,775 shares of the stock in a transaction that occurred on Wednesday, October 19th. The shares were sold at an average price of $130.11, for a total value of $881,495.25. Following the transaction, the chief executive officer now directly owns 191,358 shares in the company, valued at $24,897,589.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Michael Tang sold 3,600 shares of the business’s stock in a transaction on Tuesday, November 1st. The shares were sold at an average price of $139.50, for a total transaction of $502,200.00. Following the sale, the senior vice president now directly owns 43,280 shares of the company’s stock, valued at approximately $6,037,560. The disclosure for this sale can be found here. Insiders sold 35,309 shares of company stock worth $4,846,147 over the last three months.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. AIA Group Ltd increased its stake in Agilent Technologies by 39.6% in the 1st quarter. AIA Group Ltd now owns 4,961 shares of the medical research company’s stock worth $656,000 after buying an additional 1,408 shares in the last quarter. First Bank & Trust grew its position in shares of Agilent Technologies by 19.1% during the second quarter. First Bank & Trust now owns 924 shares of the medical research company’s stock worth $110,000 after purchasing an additional 148 shares in the last quarter. Associated Banc Corp raised its stake in Agilent Technologies by 19.5% during the 1st quarter. Associated Banc Corp now owns 3,053 shares of the medical research company’s stock valued at $404,000 after purchasing an additional 499 shares during the period. National Bank of Canada FI lifted its holdings in Agilent Technologies by 1.3% in the 1st quarter. National Bank of Canada FI now owns 48,219 shares of the medical research company’s stock worth $6,242,000 after purchasing an additional 600 shares in the last quarter. Finally, American Trust boosted its stake in Agilent Technologies by 195.7% in the 1st quarter. American Trust now owns 4,581 shares of the medical research company’s stock worth $606,000 after purchasing an additional 3,032 shares during the period.
About Agilent Technologies
(Get Rating)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.
Featured Stories
- Get a free copy of the StockNews.com research report on Agilent Technologies (A)
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
- Want to Get a 10% Dividend Yield, Look Here
- NVIDIA Corporation: Too Many Comeback Catalysts to Ignore
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agilent Technologies, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Agilent Technologies wasn’t on the list.
While Agilent Technologies currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Complete the form below to receive the latest headlines and analysts’ recommendations for your stocks with our free daily email newsletter:
Sign up for MarketBeat All Access to gain access to MarketBeat’s full suite of research tools:
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat’s trending stocks report.
Identify stocks that meet your criteria using seven unique stock screeners. See what’s happening in the market right now with MarketBeat’s real-time news feed. Export data to Excel for your own analysis.
As Featured By:
326 E 8th St #105, Sioux Falls, SD 57103
contact@marketbeat.com
(844) 978-6257
© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.